ÂÜÀòÂÒÂ×

Dennis Benjamin is a seasoned professional in the biotech and pharmaceutical industries, currently serving as Principal at Heceta BioSciences since October 2019, providing advisory services. Benjamin holds multiple positions as a member of the Scientific Advisory Board (SAB) for several companies, including Xenimmune, Manifold Bio, and Elpis Biopharmaceuticals, where also acts as Chairman and Research Fellow. Previous roles include Senior Vice President of Research and Vice President of Translational Research at Seattle Genetics, and Senior Director of Experimental Therapeutics at Praecis Pharmaceuticals. Academically, Benjamin possesses a Hitchings-Elion Postdoctoral Fellowship in Protein Chemistry from the University of Oxford, a Ph.D. in Medicinal Chemistry from the University of California, San Francisco, and a B.Sc. in Chemistry from the Massachusetts Institute of Technology.